Newsbenzinga
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…